Cynata Therapeutics

Gain a direct line to Cynata Therapeutics leadership

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Contact Us

Pre-Clinical Development

Clinical Development

Products & Pipeline

Scientific Publications

Intellectual Property

Cymerus™ Platform

Our technology

Board of Directors

About us

Company FAQs

Corporate Governance

Analyst Research

Investor FAQs

Financial Reports

Right to Receive Documents

Investor Presentations

Share Price

Announcements

Investors

Updates

Home

Frank Ruhl Libre

Read full article

Kelly_2024_CYP-001-Ph1-SR-aGvHD-2yr-follow-up.pdf

The first completed clinical trial of induced pluripotent stem cell (iPS cell)-derived cells was conducted in 15 participants with steroid-resistant acute graft-versus-host disease. After intravenous infusion of mesenchymal stromal cells (CYP-001 derived from a clone of human iPS cells), we reported the safety, tolerability and efficacy within the primary evaluation period at day 100. We now report results at the 2-year follow-up: 9 of 15 (60%) participants survived, which compares favorably with previously reported outcomes in studies of steroid-resistant acute graft-versus-host disease. Causes of death were complications commonly observed in recipients of allogeneic hematopoietic stem cell transplantation, and not considered by the investigators to be related to CYP-001 treatment. There were no serious adverse events, tumors or other safety concerns related to CYP-001. In conclusion, systemic delivery of iPS cell-derived cells was safe and well tolerated over 2 years of follow-up, with sustained outcomes up to 2 years after the first infusion. ClinicalTrials.gov registration: NCT02923375.

Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease